Icahn School of Medicine, Champions Oncology Evaluating Breast Cancer PGx Technology | GenomeWeb

NEW YORK (GenomeWeb) – The Icahn School of Medicine at Mt. Sinai and Champions Oncology today announced the start of a clinical trial to evaluate the use of the firm's Champions TumorGrafts technology in 100 patients with triple-negative breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.